Xenon Pharmaceuticals earnings were -$409.2M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest XENE earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$110.7M, up 8.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, XENE reported annual earnings of -$345.9M, with 47.6% growth.
Xenon Pharmaceuticals Earnings Reports & History FAQ
What were Xenon Pharmaceuticals's earnings last quarter?
On XENE's earnings call on Aug 6, 2026, Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 2026 earnings per share (EPS) of -$1.11, up 3.74% year over year. Total XENE earnings for the quarter were -$110.74 million. In the same quarter last year, Xenon Pharmaceuticals's earnings per share (EPS) was -$1.07.
Is Xenon Pharmaceuticals profitable or losing money?
As of the last Xenon Pharmaceuticals earnings report, Xenon Pharmaceuticals is currently losing money. Xenon Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$409.20 million, a 47.07% increase year over year.
What was XENE's earnings growth in the past year?
As of Xenon Pharmaceuticals's earnings date in Aug 6, 2026, Xenon Pharmaceuticals's earnings has grown year over year. XENE earnings in the past year totalled -$409.20 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.